Samsung Bioepis Continues G

  • Samsung Bioepis’ BRENZYS™ (etanercept) becomes      available in Brazil through Brazil’s public health system, Sistema Único      de Saúde (SUS)

  • Established seven years ago, Samsung Bioepis’      products are now available across five continents: North America, Europe,      Asia, Oceania, and Latin America. 

INCHEON, KOREA -- (BUSINESS WIRE) --

Samsung Bioepis Co., Ltd. today announced its expansion into the Brazilian biopharmaceutical market. The first product available in the country is BRENZYS™ (etanercept), a biosimilar referencing ENBREL®.i BRENZYS™ was approved by Agência Nacional de Vigilância Sanitária (ANVISA), the country’s health regulatory agency, in December 2017 for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and non-radiographic axial spondyloarthritis.

Samsung Bioepis is continuing its business expansion in multiple markets across the world, including mainland China, where the company entered into partnerships with 3SBio and C-Bridge Capital to develop and commercialize multiple biosimilar candidates from Samsung Bioepis.

BRENZYS™ is being supplied to Sistema Único de Saúde (SUS), the country’s public health system, through a Productive Development Partnership (PDP) between Samsung Bioepis and local partners, Bionovis and Bio-Manguinhos/Fiocruz.

Under the PDP, Samsung Bioepis will supply biosimilar products or product intermediaries to the local partners for sale to SUS for a period of 10 years. During this period, Samsung Bioepis will provide technology transfer to the local partners, so that manufacturing responsibilities can be gradually transferred to enable local manufacturing in Brazil. The PDP scheme was introduced by the Brazilian government in 2008, in order to expand access to medicines and support the country’s pharmaceutical industry through technology transfer from established companies in return for guaranteed purchases from SUS.

In Brazil, over 75% of patients nationwide rely on SUS for health care coverage.ii While biologics represent approximately 4% of all medicinal products acquired by SUS, they account for approximately 51% of government spending on medicinal products.iii

“We are excited to provide our high-quality biosimilars to patients across Brazil, and look forward to working with our local partners to enhance patient access to high-quality healthcare. Equally important, by sharing our scientific knowledge with our local partners, we hope to do our part in contributing to the long-term development of the Brazilian biopharmaceutical industry,” said Sang-Jin Pak, Senior Vice President and Head of Commercial Division, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and health care systems across the world.”

Samsung Bioepis’ products are now available across five continents: North America, Europe, Asia, Oceania, and Latin America. The company currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab), as well as an oncologic biosimilar, ONTRUZANT® (trastuzumab). Over 170,000 patients are currently under treatment with Samsung Bioepis’ biosimilars in Europe. In the United States, the company has one biosimilar – RENFLEXIS® (infliximab-abda) – approved and marketed. ONTRUZANT® (trastuzumab-dttb) received approval from the U.S. Food and Drug Administration (FDA) in January 2019, while ETICOVO™ (etanercept-ykro) and HADLIMA™ (adalimumab-bwwd) received FDA approval in April and July 2019, respectively.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

_____________________________
i ENBREL is a registered trademark of Pfizer
ii Jurberg C, Humphreys G. Brazil's march towards universal coverage. Bull World Health Organ. 2010;88(9):646-7.
iii Debiasi M, et al. Biosimilars in Brazil: The Beginning of an Era of Broader Access. Journal of Cancer Therapy. 2017; 8:814-826.


相关推荐
新闻聚焦
猜你喜欢
热门推荐
  • 中国新闻传媒集团三周年庆典活动在南京

      来自全国各地的嘉宾云集南京,只是为了庆祝中国新闻传媒成立三周年。 今天的盛会,是中国新闻传媒集团向社会汇报三年......

    09-28    来源:意不尽网

    分享
  • 新县绿和公益举行"气候变化警示牌"揭

      意不尽网讯(记者 阮中华) 10月3日上午,新县绿和公益协会志愿者代表与河南省生态文明建设促进会生态文化传播大使、罗......

    10-04    来源:意不尽网

    分享
  • 陕西咸阳中院“伪造”鉴定机构妨碍司法

      记者报讯 :近日,陕西君寿堂制药有限公司(原告)反应,咸阳市中级人民法院利用职权私自委托没有经过摇号选定的司法......

    12-24    来源:记者报

    分享
  • 新中国成立70周年华诞暨中国传媒新闻集

      本网讯(阮中华 张国强 摄影 董万芳) 2019年9月27日,为庆祝新中国成立70周年暨中国新闻传媒集团成立三周年庆典在南京市......

    09-30    来源:意不尽网

    分享
  • 抗美援朝老兵庆祝70周年华诞活动在中国

      中国老兵事业发展中心讯(袁建国) 时间的年轮,记录着奋斗者的足迹,也见证了中华人民共和国日新月异的变化和激荡的......

    10-02    来源:中国老兵事业发展中心

    分享
  • “气候变化警示牌”亮相墨尔本、悉尼

      本网讯(阮中华) 11月18日至26日,受2030计划委托,2030计划气候使者、绿色旅游世界行发起人王晨琛将人类行为导致气候变化......

    11-29    来源:意不尽网

    分享
  • 全球首个“气候受难者纪念碑”落成仪式

      意不尽网讯(梅东霞) 10月28日上午11时,由北京绿十字、河南省生态文明建设促进会千手行动组委会主办,乡宿.郝堂花间驿......

    10-29    来源:意不尽网

    分享
  • “人类行为导致气候变化警示牌“落户罗

      意不尽网讯(杜永友) 10月21日上午,人类行为导致气候变化警示牌揭牌仪式在罗山县涩港高中校园隆重举行,这是迄今为止......

    10-23    来源:意不尽网

    分享
  • 第三届“寻找最美海外中国游客”在徐霞

      意不尽网讯(阮中华) 10月19日下午,浙江省宁海县图书馆内座无虚席、气氛热烈,第三届寻找最美海外中国游客颁奖暨当代......

    10-21    来源:意不尽网

    分享
  • “人类行为导致气候变化警示碑”揭碑仪

      意不尽网讯(文:杜永友;诗:白露;摄影:李绍清、喻刚、高振林) 囯庆70周年即将到来之际,9月30日下午3点,艳阳高照......

    10-01    来源:意不尽网

    分享
返回列表
Ctrl+D 将本页面保存为书签,全面了解最新资讯,方便快捷。